Kiniksa Pharmaceuticals (KNSA) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free KNSA Stock Alerts $19.77 -0.34 (-1.69%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:59 AM | marketbeat.comJump Financial LLC Makes New $951,000 Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jump Financial LLC bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 54,220 shares of the company's stockMay 16 at 5:12 AM | americanbankingnews.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Up 7.4% in AprilMay 10, 2024 | markets.businessinsider.comMarket Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry IndicatorsMay 7, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceMay 4, 2024 | msn.comWells Fargo Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Overweight RecommendationMay 3, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated at Wells Fargo & CompanyWells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday. They set an "overweight" rating and a $34.00 target price on the stock.May 1, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the stock an "overweight" rating in a research report on Wednesday.April 26, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter ReportApril 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call TranscriptApril 25, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per ShareKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush raised their Q2 2024 earnings per share estimates for Kiniksa Pharmaceuticals in a report released on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per shApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug ProspectsApril 24, 2024 | markets.businessinsider.comCan Growing Adoption Of Arcalyst Drive KNSA Stock Up?April 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take ShapeApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call TranscriptApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 24, 2024 | marketbeat.comEvercore ISI Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $30.00Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday.April 24, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPSKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The firm had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. During the same quarter last year, the company earned ($0.18) earnings per share. The firm's revenue was up 65.4% on a year-over-year basis.April 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial ExecutionApril 23, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday.April 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call PresentationApril 23, 2024 | msn.comKiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlookApril 23, 2024 | markets.businessinsider.comKNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024April 23, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue ForecastsApril 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionApril 20, 2024 | investing.comKiniksa Pharmaceuticals Ltd (KNSA)April 17, 2024 | marketbeat.comKiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, April 23, Zacks reports.April 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024April 9, 2024 | marketbeat.comVanguard Group Inc. Sells 128,255 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Vanguard Group Inc. trimmed its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 4.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,958,957 shares of the company's stock after selling 128April 5, 2024 | marketbeat.comWedbush Research Analysts Reduce Earnings Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush decreased their FY2024 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the cApril 4, 2024 | marketbeat.comFY2027 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Reduced by WedbushKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush dropped their FY2027 earnings estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the company will earn $0.15 per shaApril 3, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 3.6% Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 3.6%April 2, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns "Outperform" Rating from WedbushWedbush restated an "outperform" rating and issued a $30.00 price target (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a report on Tuesday.April 2, 2024 | globenewswire.comKiniksa Pharmaceuticals Announces Development Indication for AbiprubartMarch 16, 2024 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 5,582 Shares of StockMarch 15, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lowered by Hudson Bay Capital Management LPHudson Bay Capital Management LP trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 55.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 302,500 shares of the compaMarch 12, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by AQR Capital Management LLCAQR Capital Management LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 36.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 323,578 shares of the company's stock after selling 187March 7, 2024 | msn.com5 Biotech Stocks With 26% Upside Potential or MoreMarch 6, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Buys 134,070 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Schonfeld Strategic Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 180.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 208,500 shares of the company's stock after purchasing an addMarch 4, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 12-Month High at $22.09Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 52-Week High at $22.09March 3, 2024 | investing.comEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesMarch 3, 2024 | wsj.comKiniksa Pharmaceuticals Ltd.March 1, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 5,126 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 5,126 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at approximately $383,242.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 1, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | marketbeat.comQ1 2024 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. Boosted by Analyst (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Analysts at Wedbush lifted their Q1 2024 earnings estimates for shares of Kiniksa Pharmaceuticals in a research note issued on Wednesday, February 28th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings peMarch 1, 2024 | finance.yahoo.comChief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)February 29, 2024 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great ChoiceFebruary 29, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketbeat.comWedbush Weighs in on Kiniksa Pharmaceuticals, Ltd.'s Q1 2025 Earnings (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates thaFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA) Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond KNSA Media Mentions By Week KNSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.830.42▲Average Medical News Sentiment KNSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼32▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arcus Biosciences News ANI Pharmaceuticals News Day One Biopharmaceuticals News Xencor News Morphic News Protagonist Therapeutics News Akero Therapeutics News Dynavax Technologies News Gemini Therapeutics News Ligand Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
